Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast

Michele Columbo

Published: 17 April 2017

Abstract

Background

Little is known about asthma in the elderly as most studies of this condition have not included this patient group. It is unclear whether leukotriene antagonists benefit older asthmatics. We studied the effect of adding montelukast to the asthma treatment of elderly subjects.

Methods

Twenty-five subjects 65 years old and older with asthma were evaluated at week 0, 1, 5, 9, 13, and 17. Each subject received montelukast 10 mg and placebo each for 8 weeks in a cross-over design.

Results

Montelukast for 4 or 8 weeks did not significantly affect ACT, daily symptom scores, number of puffs of albuterol, spirometric values, peripheral blood eosinophils, or serum IgE vs. baseline or placebo. Similar results were obtained when analyzing subgroups of patients with lower ACT, lower FEV1, and higher eosinophils.

Conclusions

In this study of elderly asthmatics, montelukast had no effect on asthma symptoms, number of puffs of albuterol, spirometric values, peripheral blood eosinophils or serum IgE. These results will require confirmation in larger patient cohorts and in patients with uncontrolled asthmatic symptoms.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Jason K Lee on Twitter: "Potential treatment for pollen food syndrom… https://t.co/SHnw9UVPnw, see more https://t.co/CpGiFuOOYd
13mreplyretweetfavorite
Interasma Top story: @worldallergy: '#EAACI2018 Understanding phenotypes and endotypes in… https://t.co/WcFkKLobbc, see more https://t.co/CpGiFuOOYd
2hreplyretweetfavorite
Interasma Top story: EAACI on Twitter: "Announcing #EAACI2018 #SisterSocietySymposium SSS… https://t.co/Wic8jRgFE8, see more https://t.co/CpGiFuOOYd
6hreplyretweetfavorite
Interasma Top story: Graham Roberts on Twitter: "Severe asthma plenary #EAACI2018 - no me… https://t.co/ssW67QWKyG, see more https://t.co/CpGiFuOOYd
18hreplyretweetfavorite
Interasma RT @worldallergy: #EAACI2018 Understanding phenotypes and endotypes in severe #asthma https://t.co/MMyACUQd5c
20hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma